Lineage Stock Today

LCTX
 Stock
  

USD 1.66  0.01  0.60%   

Market Performance
6 of 100
Odds Of Distress
Less than 2
Lineage Cell is trading at 1.66 as of the 7th of July 2022; that is -0.6 percent decrease since the beginning of the trading day. The stock's open price was 1.67. Lineage Cell has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Lineage Cell Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2022 and ending today, the 7th of July 2022. Please note, there could be an existing legal relationship between Lineage Cell Therapeutics (LCTX) and Brooklyn Immunotherapeuti (BTX). Click here to learn more.
CUSIP
09066L105
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of March 1992
Category
Healthcare
Classification
Health Care
ISIN
US53566P1093
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. The company has 168.56 M outstanding shares of which 10.07 M shares are now shorted by private and institutional investors with about 14.45 trading days to cover. More on Lineage Cell Therapeutics

Moving together with Lineage Cell

0.72CVMCel-Sci Corp Normal TradingPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Lineage Cell Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Lineage Cell's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lineage Cell or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Lineage Cell may become a speculative penny stock
Lineage Cell has very high historical volatility over the last 90 days
Lineage Cell is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 4.34 M. Net Loss for the year was (43.02 M) with profit before overhead, payroll, taxes, and interest of 2.92 M.
Lineage Cell Therapeutics currently holds about 58.36 M in cash with (23.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Latest headline from MacroaxisInsider: Exercise or conversion by Culley Brian M of 15450 shares of Lineage Cell subject to Rule 16b-3
Related EntityBTX (Brooklyn Immunotherapeutics)
Fama & French Classification
Average Analyst Recommendation
Analysts covering Lineage Cell report their recommendations after researching Lineage Cell's financial statements, talking to executives and customers, or listening in on Lineage Cell's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Lineage Cell Therapeutics. The Lineage consensus assessment is calculated by taking the average forecast from all of the analysts covering Lineage Cell.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Lineage Cell Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Lineage Cell Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares144.2 M164.5 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted144.4 M164.5 M
Fairly Down
Increasing
Slightly volatile
Total Assets151.3 M174.5 M
Fairly Down
Increasing
Slightly volatile
Total Liabilities90.3 M83.6 M
Significantly Up
Increasing
Slightly volatile
Current Assets120.4 M111.5 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities50.8 M47.1 M
Significantly Up
Increasing
Slightly volatile
Total Debt3.3 M2.8 M
Fairly Up
Increasing
Slightly volatile
Return on Average Assets(0.33)(0.303)
Significantly Down
Increasing
Slightly volatile
Gross Margin0.720.672
Notably Up
Decreasing
Slightly volatile
Asset Turnover0.04140.031
Significantly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Lineage Cell's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Lineage Cell's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Lineage Cell's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lineage Cell's financial leverage. It provides some insight into what part of Lineage Cell's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Lineage Cell's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Lineage Cell deploys its capital and how much of that capital is borrowed.
Liquidity
Lineage Cell cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.8 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Lineage Cell Therapeutics has a current ratio of 2.32, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lineage Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Lineage Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lineage Cell Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lineage to invest in growth at high rates of return. When we think about Lineage Cell's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(25.42 Million)
Lineage Cell Therapeutics (LCTX) is traded on NYSEMKT Exchange in USA. It is located in 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008, United States and employs 57 people. Lineage Cell is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 281.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lineage Cell's market, we take the total number of its shares issued and multiply it by Lineage Cell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Lineage Cell Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 168.56 M outstanding shares of which 10.07 M shares are now shorted by private and institutional investors with about 14.45 trading days to cover. Lineage Cell Therapeutics currently holds about 58.36 M in cash with (23.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Check Lineage Cell Probability Of Bankruptcy
Ownership
Lineage Cell Therapeutics maintains a total of one hundred sixty-eight million five hundred sixty thousand outstanding shares. 30% of Lineage Cell outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Lineage Ownership Details

Lineage Stock Price Odds Analysis

What are Lineage Cell's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Lineage Cell jumping above the current price in 90 days from now is near 1%. The Lineage Cell Therapeutics probability density function shows the probability of Lineage Cell stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0202. This indicates Lineage Cell Therapeutics market returns are sensitive to returns on the market. As the market goes up or down, Lineage Cell is expected to follow. Additionally, the company has an alpha of 0.3948, implying that it can generate a 0.39 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 1.67HorizonTargetOdds Above 1.67
99.07%90 days
 1.67 
0.92%
Based on a normal probability distribution, the odds of Lineage Cell to move above the current price in 90 days from now is near 1 (This Lineage Cell Therapeutics probability density function shows the probability of Lineage Stock to fall within a particular range of prices over 90 days) .

Lineage Cell Historical Income Statement

Lineage Cell Therapeutics Income Statement is one of the three primary financial statements used for reporting Lineage's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lineage Cell Therapeutics revenue and expense. Lineage Cell Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Lineage Cell Direct Expenses is fairly stable at the moment as compared to the past year. Lineage Cell reported Direct Expenses of 1.43 Million in 2021. Cost of Revenue is likely to rise to about 1.5 M in 2022, whereas Consolidated Income is likely to drop (46.7 M) in 2022. View More Fundamentals

Lineage Stock Against Markets

Picking the right benchmark for Lineage Cell stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lineage Cell stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lineage Cell is critical whether you are bullish or bearish towards Lineage Cell Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lineage Cell without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Investing Lineage Cell Therapeutics

You need to understand the risk of investing before taking a position in Lineage Cell. The danger of trading Lineage Cell Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lineage Cell is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lineage Cell. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lineage Cell Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Lineage Cell Therapeutics information on this page should be used as a complementary analysis to other Lineage Cell's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Lineage Stock analysis

When running Lineage Cell Therapeutics price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Lineage Cell's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lineage Cell. If investors know Lineage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lineage Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
286.8 M
Quarterly Revenue Growth YOY
12.39
Return On Assets
-0.21
Return On Equity
-0.48
The market value of Lineage Cell Therapeutics is measured differently than its book value, which is the value of Lineage that is recorded on the company's balance sheet. Investors also form their own opinion of Lineage Cell's value that differs from its market value or its book value, called intrinsic value, which is Lineage Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lineage Cell's market value can be influenced by many factors that don't directly affect Lineage Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lineage Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine Lineage Cell value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lineage Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.